Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.

Boehringer’s lung drug Spiriva, approved for chronic obstructive pulmonary disease (COPD) and asthma, generated net sales of 2.4 billion euros, down 11.4% compared with last year, which the ...

As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO.

Objective: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor ...

* From the Critical Care Department (Dr. Dimopoulos), "Attikon" University Hospital, Athens, Greece; and Alfa Institute of Biomedical Sciences (Drs. Siempos, Korbila, Manta, and Falagas), Athens ...